Abstract: A pharmaceutical composition comprising a solid unit dosage form comprising: (i) ritonavir or a pharmaceutically acceptable salt and ester thereof; (ii) darunavir or a pharmaceutically acceptable salt and ester thereof.

Abstract: The invention relates to a valve for an aerosol device. More specifically the invention relates to a valve for an aerosol device for a Metered Dose Inhaler. The valve assembly (60) is receivable in an opening (68) provided in a container (66) of the aerosol device (76) to close said opening (68). The valve assembly is provided with means (58) for forming a seal between the valve assembly (60) and the container (66).

Abstract: A pharmaceutical product or formulation, which comprises azelastine or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and a steroid, or a pharmaceutical acceptable salt, solvate or physiologically functional derivative thereof, preferably the product or formulation being in a form suitable for nasal or ocular administration.

Abstract: The invention relates to pharmaceutical compositions containing a combination of atazanavir and ritonavir, to methods of making them, and their use in medicine.

Abstract: The invention relates to an aerosol device. More specifically the invention relates to an aerosol device for a Metered Dose Inhaler. The aerosol device (76,176) comprises a container (66,166) with an opening at one end, a self sealing valve assembly (60,160) supported within the container (66,166), and a cap member (72,172) for maintaining the valve assembly (60,160) in the container (66,166), wherein the cap member (72,172) is secured to the container (66,166) in order to retain the valve assembly (60,160) in position.

Abstract: Amorphous HMG CoA reductase inhibitors, especially amorphous atorvastatin, are described. Also described are pharmaceutical combinations comprising amorphous HMG CoA reductase inhibitors in combination with cholesterol absorption inhibitors or fibrates. A method of manufacturing the compositions using a hot melt extrusion process are also described.

Abstract: The present invention provides an antiretroviral solid oral composition comprising one or more antiretroviral drugs, for example protease inhibitors such as lopinavir, ritonavir or a combination thereof with one or more excipients. The invention provides a composition which is smaller for a given amount of said active substance and possesses taste masking property and a process for preparing the composition. The present invention also provides an antiretroviral solid oral composition comprising one or more antiretroviral drugs, for example protease inhibitors such as lopinavir, ritonavir or a combination thereof with at least one water insoluble polymer, wherein the ratio of drug to polymer in the composition ranges from about 1:1 to about 1:6, and a process for preparing the composition.

Abstract: The present invention provides an inhaler device (1) for dispensing multiple doses of medicament, the inhaler comprising medicament extraction facilitating means (22) for locating adjacent or in a compartment (42) of a received medicament cartridge and thereby allowing an extraction of medicament from the compartment; and operating means (54) moveable in first and second directions by a user. The medicament extraction facilitating means is movable from a retracted position to an extraction position in response to movement of the operating means in the first direction. The extraction position allows extraction of medicament from said cartridge compartment upon inhalation by a user, and the retracted position allows advancement of the medicament cartridge. The medicament cartridge is driven by the operating means so as to advance a cartridge compartment into a predetermined position relative to the extraction facilitating means in response to movement of the operating means in the second direction.

Abstract: A pharmaceutical combination comprising (a) a combination of two or more bronchodilators; or (b) a combination of at least one bronchodilator in combination with at least one corticosteroid.

Abstract: An inhaler (1) device for inhalation of a medicament from a pierceable capsule (10) comprises a housing (2) for receiving a medicament, capsule, closure means (3) for closing the housing, said closure means being moveable relative to the housing; piercing means (7) suitable for piercing a medicament capsule; wherein movement of the closure means relative to the housing causes movement of the piercing means, and wherein the device comprises an air inlet (71) and an air outlet (72) defining an inhalation passage therebetween, the passage comprising one or more vents (70).

Abstract: A stable aqueous pharmaceutical composition comprising anhydrous mometasone furoate and a pharmaceutically acceptable carrier.

Abstract: A pharmaceutical product or formulation, which comprises azelastine or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and a steroid, or a pharmaceutical acceptable salt, solvate or physiologically functional derivative thereof, preferably the product or formulation being in a form suitable for nasal or ocular administration.

Abstract: A pharmaceutical product or formulation, which comprises azelastine or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and a steroid, or a pharmaceutical acceptable salt, solvate or physiologically functional derivative thereof, preferably the product or formulation being in a form suitable for nasal or ocular administration.

Abstract: The invention provides three polymorphic forms of crystalline levosalbutamol sulphate designated herein as Forms I, II and III. Crystalline levosalbutamol sulphate Form I is characterised by a powder XRD pattern with peaks at 10.8, 11.9, 13.0, 18.3, 28.5±0.2 degrees 2 theta. Crystalline levosalbutamol sulphate Form II is characterised by a powder XRD pattern with peaks at 8.7, 9.6, 15.2, 15.7, 19.1, 27.2, 30.7±0.2 degrees 2 theta. Crystalline levosalbutamol sulphate Form III is characterised by a powder XRD pattern with peaks at 5.5, 6.9, 7.3, 18.7±0.2 degrees 2 theta. Processes for making the new polymorphic forms and pharmaceutical compositions comprising them are also provided. A pharmaceutical composition comprises a therapeutically effective isomer of salbutamol or a salt, solvate, ester, derivative or polymorph thereof, a glucocorticoid and a pharmaceutically acceptable carrier or excipient and optionally one or more other therapeutic agents.